Literature DB >> 11431355

Identification of T helper epitopes from prostatic acid phosphatase.

D G McNeel1, L D Nguyen, M L Disis.   

Abstract

Helper T cells (Th cells) play a central role in the initiation and maintenance of immune responses, including antitumor immunity. The ability of Th cells in murine models to maintain and enhance the cytolytic efficacy of CD8+ CTLs has led to a renewed interest in identifying human tumor antigens recognized by Th cells. Prostatic acid phosphatase (PAP) is a prostate cancer-associated tumor antigen. A rodent model has demonstrated that PAP-specific CTLs can induce destructive prostatitis. Human MHC class I epitopes derived from PAP have been identified previously, and peptide-specific CTLs have been shown to be able to lyse an MHC-restricted prostate cancer cell line. In the current study, we sought to identify Th epitopes derived from PAP that might be used to elicit PAP-specific Th responses, ultimately in the context of human vaccines targeting PAP. Using peripheral blood mononuclear cells (PBMCs) from subjects with and without PAP-specific Th responses, we screened a panel of 10 potential peptide epitopes for peptide-specific T-cell proliferation. Four peptides, p81-95, p199-213, p228-242, and p308-322, were identified for which peptide-specific T-cell proliferation occurred in the majority of patient PBMC samples that also exhibited PAP-specific T-cell proliferation. PBMCs from patients with prostate cancer and without PAP-specific Th immunity were then cultured in vitro with these four peptides. Peptide-specific T-cell lines could be generated from two of the four peptides, p199-213 and p228-242, that also proliferated in response to PAP protein stimulation. The ability of these two peptides to elicit PAP-specific Th responses suggests that they represent naturally processed PAP-specific MHC class II epitopes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431355

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Immunotherapy for prostate cancer: biology and therapeutic approaches.

Authors:  Edward Cha; Lawrence Fong
Journal:  J Clin Oncol       Date:  2011-08-08       Impact factor: 44.544

2.  MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment.

Authors:  Navreet K Nanda; Lynn Birch; Norman M Greenberg; Gail S Prins
Journal:  Prostate       Date:  2006-09-01       Impact factor: 4.104

3.  Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.

Authors:  Paul F Schellhammer; Robert M Hershberg
Journal:  World J Urol       Date:  2005-01-13       Impact factor: 4.226

4.  Immunotherapy and immune evasion in prostate cancer.

Authors:  Archana Thakur; Ulka Vaishampayan; Lawrence G Lum
Journal:  Cancers (Basel)       Date:  2013-05-24       Impact factor: 6.639

Review 5.  Sipuleucel-T: immunotherapy for advanced prostate cancer.

Authors:  Brian M Olson; Douglas G McNeel
Journal:  Open Access J Urol       Date:  2011-05-03

6.  Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Authors:  Bently P Doonan; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2015-08-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.